Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) does about 290.48K shares in volume on a normal day but saw 2402756 shares change hands in the recent trading day. The company now has a market cap of 2.84M USD. Its current market price is $1.32, marking an increase of 15.79% compared to the previous close of $1.14. The 52 week high reached by this stock is $11.34 whilst the lowest price level in 52 weeks is $0.75.
Cyclacel Pharmaceuticals Inc (CYCC) has a 20-day trading average at $0.9543 and the current price is -88.36% off the 52-week high compared with 76.00% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.0632 and its 200-day simple moving average is $1.8413. If we look at the stock’s price movements over the week, volatility stands at 33.63%, which decreases to 13.90% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 73.38 to suggest the stock is overbought.
The consensus objective for the share price is $11.00, suggesting that the stock has a potential upside of 88.0% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 18, 2022 when Oppenheimer resumed the stock to “Outperform” and issued a price target of $17.
The current price level is 38.33%, 24.16%, and -28.31% away from its SMA20, SMA50, and SMA200 respectively, with the CYCC price moving below the 50-day SMA on current market day. Cyclacel Pharmaceuticals Inc (CYCC) stock is up 65.00% over the week and 34.69% over the past month. Its price is -50.56% year-to-date and -86.29% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -7.35 below consensus estimates by -1.9. The company’s next earnings report forecasts estimating quarterly EPS at -0.55 and -3.13 for whole year.
To reach the target analysts have set, the stock logically needs to grow 88.0 percent from here.
Outstanding shares total 2.15M with insiders holding 4.82% of the shares and institutional holders owning 18.03% of the company’s common stock. The company has a return on investment of -1753.59% and return on equity of -329.40%. The beta has a value of 0.52. Price to book ratio is 2.39 and price to sales ratio is 35.48.
